PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series

References

• Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929. doi:10.1002/pbc.27929
   PubMed Web of Science ®Google Scholar
• Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1):S82. doi:10.1016/j.bbmt.2009.11.014
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang P, Bao Y. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: a single center retrospective analysis. Front Immunol. 2023;14:1093719. doi:10.3389/fimmu.2023.1093719
   PubMed Web of Science ®Google Scholar
• Pi Y, Wang J, Wang Z. Massive pericardial effusion due to chronic active Epstein-Barr virus infection successfully treated with PD-1 blockade: a case report. Medicine. 2022;101(34):e30298. doi:10.1097/MD.0000000000030298
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:10.1038/s41572-020-0160-6
   PubMed Web of Science ®Google Scholar
• Rosée P L, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.2018894618
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017:439.
   Google Scholar
• Henter JI, Elinder G; Ost a, and the FHL study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol. 1991;1:29–33.
   Google Scholar
• Cheng J, Niu J, Wang Y. Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of the literature. J Obstet Gynaecol. 2020;40(2):153–159. doi:10.1080/01443615.2019.1601168
   PubMedGoogle Scholar
• Strenger V, Merth G, Lackner H, et al. Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents—a single centre experience of 20years. Springer Open Choice. 2018;97(6):989–998.
   Google Scholar
• Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Baillières Best Pract Res Clin Rheumatol. 2020;34(4):101515. doi:10.1016/j.berh.2020.101515
   PubMed Web of Science ®Google Scholar
• Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int j Hematol. 2017;105(4):406e18. doi:10.1007/s12185-017-2192-6
   Web of Science ®Google Scholar
• Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135(11):826–833. doi:10.1182/blood.2019003886
   PubMed Web of Science ®Google Scholar
• Lin N, Song Y, Zhu J. Immune checkpoint inhibitors in malignant lymphoma: advances and perspectives. Chin J Cancer Res. 2020;32(3):303e18. doi:10.21147/j.issn.1000-9604.2020.03.03
   Web of Science ®Google Scholar
• Song Y, Wang J, Wang Y, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clin Microbiol Infect. 2023;29(6):796–e7.
   Web of Science ®Google Scholar
• Pi Y, Wang J, Wang Z. Successful treatment of relapsed Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis after Allo-HSCT with PD-1 blockade: a case report. Infect Drug Resist. 2022;15:3751–3756. doi:10.2147/IDR.S372998
   PubMed Web of Science ®Google Scholar
• Holmes Z, Courtney A, Hiong A. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy. BMJ Case Rep. 2022;15(8):e251052. doi:10.1136/bcr-2022-251052
   PubMedGoogle Scholar
• Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328–340. doi:10.1182/blood-2013-03-489708
   PubMed Web of Science ®Google Scholar
• Liu LL, Skribek M, Harmenberg U, et al. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. Journal for ImmunoTherapy of Cancer. 2023;11(3):e005841. doi:10.1136/jitc-2022-005841
   PubMed Web of Science ®Google Scholar
• Malissen N, Lacotte J, Du-Thanh A, et al. Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer. 2017;77:88–89. doi:10.1016/j.ejca.2017.02.016
   PubMed Web of Science ®Google Scholar
• He L, Zhuang Y, Zhang D, et al. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: a cautionary case report. Transfus Apheresis Sci. 2023;62(2):103603. doi:10.1016/j.transci.2022.103603
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186–2192. doi:10.1182/blood-2015-05-644914
   PubMed Web of Science ®Google Scholar
• Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84–91. doi:10.4049/jimmunol.1302282
   PubMed Web of Science ®Google Scholar
• Huwyler J, Drewe J, Kr€ahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed. 2008;3(1):21–29. doi:10.2147/IJN.S1253
   PubMed Web of Science ®Google Scholar
• Meng G, Wang Y, Wang J, et al. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis. Leukemia Lymphoma. 2021;62(4):854–860. doi:10.1080/10428194.2020.1849671
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9(1):84. doi:10.1186/s13045-016-0317-7
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang L, Wei A, et al. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection. Orphanet J Rare Dis. 2021;16(1):269. doi:10.1186/s13023-021-01909-y
   PubMed Web of Science ®Google Scholar
• Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:614704. doi:10.3389/fimmu.2021.614704
   PubMed Web of Science ®Google Scholar